Activity Overview
This online, on-demand virtual symposium brings together renowned experts in HR+/HER2– breast cancer. In this educational program, these experts discuss the evolving treatment landscape for HR+/HER2– breast cancer. The program features dynamic discussions, practical insights, and updates from pivotal clinical trials that provide actionable guidance for optimizing patient care.
This educational activity is an archive of a live virtual webcast held on June 8, 2026.
Target Audience
This educational program is primarily directed toward a global audience of medical oncologists, advanced practice providers, nurses, and other health care professionals who are involved in the management of patients with advanced or metastatic breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Identify approved and emerging oral SERDs for the management of HR+/HER2– breast cancer
- Assess emerging clinical trial and real-world evidence to gain practical insights into the appropriate use of oral SERD–based treatment strategies for patients with HR+/HER2– MBC
- Integrate clinical trial data, real-world evidence, and patient- and disease-specific factors to inform personalized treatment decisions for patients with HR+/HER2– MBC
Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and
Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader, Breast Oncology Program
UT Health San Antonio, MD Anderson Cancer Center
San Antonio, TX
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, Daiichi Sankyo, Genentech, Gilead, Menarini, Pfizer; Speakers Bureau: AstraZeneca, Gilead
Kamel Abou Hussein, MD
Assistant Professor of Medicine
Cooper Medical School of Rowan University
MD Anderson Cancer Center at Cooper
Camden, NJ
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca; Speakers Bureau: Lilly
Javier Cortés, MD, PhD
Head of the International Breast Cancer Center
Barcelona, Spain
Director of IOB Institute of Oncology Madrid
Madrid, Spain
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, Bioasis, BioInvent, Boehringer Ingelheim, Clovis Oncology, Daiichi Sankyo, Ellipses, GEMoaB, Gilead, HiberCell, Leuko, Menarini, Merck Sharp & Dohme, Roche, Seattle Genetics, Zymeworks; Speakers Bureau: AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Stemline Therapeutics; Grant/Research Funding: Ariad Pharmaceuticals, AstraZeneca, Baxalta GmbH/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffmann-La Roche; Ownership Interests in Privately Held Companies: Leuko (relative), MAJ3 Capital; Employee/Owner: International Cancer Experts S.L., MAJ3; Royalty or Patent Benefits: Pharmaceutical Combinations of a Pi3k Inhibitor and a Microtubule Destabilizing Agent—Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizald
Seth A. Wander, MD, PhD
Assistant Professor of Medicine
Harvard Medical School
Medical Oncologist
Massachusetts General Hospital
Boston, MA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Arvinas, AstraZeneca, Biovica, Boundless Bio, Celcuity, Delcath, Foundation Medicine, Genentech, Gilead, Halda Therapeutics, Hologic, Lilly, Novartis, Pfizer, Puma Biotechnology, Regor Therapeutics, Stemline Therapeutics/Menarini, Veracyte; Grant/Research Funding: Arvinas, Genentech, Lilly, Nuvation Bio, Pfizer, Phoenix Molecular Designs, Puma Biotechnology, Regor Therapeutics, Sermonix, Stemline Therapeutics/Menarini
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and
planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.
In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.
Learners are encouraged to independently evaluate the information
presented and apply their own clinical judgment when considering patient care
decisions.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
